<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang xml:lang>
<head>
  <meta charset="utf-8" />
  <meta name="generator" content="pandoc" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes" />
  <title>Your Digest for Thursday, Jun 29, 2023 11:59 PM</title>
  <style>
    code{white-space: pre-wrap;}
    span.smallcaps{font-variant: small-caps;}
    span.underline{text-decoration: underline;}
    div.column{display: inline-block; vertical-align: top; width: 50%;}
    div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
    ul.task-list{list-style: none;}
  </style>
  <style type="text/css">
:root,
::backdrop {

--sans-font: -apple-system, BlinkMacSystemFont, "Avenir Next", Avenir,
"Nimbus Sans L", Roboto, "Noto Sans", "Segoe UI", Arial, Helvetica,
"Helvetica Neue", sans-serif;
--mono-font: Consolas, Menlo, Monaco, "Andale Mono", "Ubuntu Mono", monospace;
--standard-border-radius: 5px;

--bg: #fff;
--accent-bg: #f5f7ff;
--text: #212121;
--text-light: #585858;
--border: #898EA4;
--accent: #0d47a1;
--code: #d81b60;
--preformatted: #444;
--marked: #ffdd33;
--disabled: #efefef;
}

@media (prefers-color-scheme: dark) {
:root,
::backdrop {
color-scheme: dark;
--bg: #212121;
--accent-bg: #2b2b2b;
--text: #dcdcdc;
--text-light: #ababab;
--accent: #ffb300;
--code: #f06292;
--preformatted: #ccc;
--disabled: #111;
}

img,
video {
opacity: 0.8;
}
}

*, *::before, *::after {
box-sizing: border-box;
}

textarea,
select,
input,
progress {
appearance: none;
-webkit-appearance: none;
-moz-appearance: none;
}
html {

font-family: var(--sans-font);
scroll-behavior: smooth;
}

body {
color: var(--text);
background-color: var(--bg);
font-size: 1.15rem;
line-height: 1.5;
display: grid;
grid-template-columns: 1fr min(45rem, 90%) 1fr;
margin: 0;
}
body > * {
grid-column: 2;
}

body > header {
background-color: var(--accent-bg);
border-bottom: 1px solid var(--border);
text-align: center;
padding: 0 0.5rem 2rem 0.5rem;
grid-column: 1 / -1;
}
body > header h1 {
max-width: 1200px;
margin: 1rem auto;
}
body > header p {
max-width: 40rem;
margin: 1rem auto;
}

main {
padding-top: 1.5rem;
}
body > footer {
margin-top: 4rem;
padding: 2rem 1rem 1.5rem 1rem;
color: var(--text-light);
font-size: 0.9rem;
text-align: center;
border-top: 1px solid var(--border);
}

h1 {
font-size: 3rem;
}
h2 {
font-size: 2.6rem;
margin-top: 3rem;
}
h3 {
font-size: 2rem;
margin-top: 3rem;
}
h4 {
font-size: 1.44rem;
}
h5 {
font-size: 1.15rem;
}
h6 {
font-size: 0.96rem;
}

p, h1, h2, h3, h4, h5, h6 {
overflow-wrap: break-word;
}

h1,
h2,
h3 {
line-height: 1.1;
}

@media only screen and (max-width: 720px) {
h1 {
font-size: 2.5rem;
}
h2 {
font-size: 2.1rem;
}
h3 {
font-size: 1.75rem;
}
h4 {
font-size: 1.25rem;
}
}

a,
a:visited {
color: var(--accent);
}
a:hover {
text-decoration: none;
}
button,
.button,
a.button, 
input[type="submit"],
input[type="reset"],
input[type="button"],
label[type="button"] {
border: none;
border-radius: var(--standard-border-radius);
background-color: var(--accent);
font-size: 1rem;
color: var(--bg);
padding: 0.7rem 0.9rem;
margin: 0.5rem 0;
text-decoration: none;
font-family: inherit;
line-height: normal;
}
.button[aria-disabled="true"], input:disabled,
textarea:disabled,
select:disabled,
button[disabled] {
cursor: not-allowed;
background-color: var(--disabled);
color: var(--text-light)
}
input[type="range"] {
padding: 0;
}

abbr[title] {
cursor: help;
text-decoration-line: underline;
text-decoration-style: dotted;
}
button:enabled:hover,
.button:not([aria-disabled="true"]):hover,
input[type="submit"]:enabled:hover,
input[type="reset"]:enabled:hover,
input[type="button"]:enabled:hover,
label[type="button"]:hover {
filter: brightness(1.4);
cursor: pointer;
}
.button:focus-visible,
button:focus-visible:where(:enabled),
input:enabled:focus-visible:where(
[type="submit"],
[type="reset"],
[type="button"]
) {
outline: 2px solid var(--accent);
outline-offset: 1px;
}

header > nav {
font-size: 1rem;
line-height: 2;
padding: 1rem 0 0 0;
}

header > nav ul,
header > nav ol {
align-content: space-around;
align-items: center;
display: flex;
flex-direction: row;
flex-wrap: wrap;
justify-content: center;
list-style-type: none;
margin: 0;
padding: 0;
}

header > nav ul li,
header > nav ol li {
display: inline-block;
}
header > nav a,
header > nav a:visited {
margin: 0 0.5rem 1rem 0.5rem;
border: 1px solid var(--border);
border-radius: var(--standard-border-radius);
color: var(--text);
display: inline-block;
padding: 0.1rem 1rem;
text-decoration: none;
}
header > nav a:hover,
header > nav a.current,
header > nav a[aria-current="page"] {
border-color: var(--accent);
color: var(--accent);
cursor: pointer;
}

@media only screen and (max-width: 720px) {
header > nav a {
border: none;
padding: 0;
text-decoration: underline;
line-height: 1;
}
}

aside, details, pre, progress {
background-color: var(--accent-bg);
border: 1px solid var(--border);
border-radius: var(--standard-border-radius);
margin-bottom: 1rem;
}
aside {
font-size: 1rem;
width: 30%;
padding: 0 15px;
margin-inline-start: 15px;
float: right;
}
*[dir="rtl"] aside {
float: left;
}

@media only screen and (max-width: 720px) {
aside {
width: 100%;
float: none;
margin-inline-start: 0;
}
}
article, fieldset, dialog {
border: 1px solid var(--border);
padding: 1rem;
border-radius: var(--standard-border-radius);
margin-bottom: 1rem;
}
article h2:first-child,
section h2:first-child {
margin-top: 1rem;
}
section {
border-top: 1px solid var(--border);
border-bottom: 1px solid var(--border);
padding: 2rem 1rem;
margin: 3rem 0;
}

section + section,
section:first-child {
border-top: 0;
padding-top: 0;
}
section:last-child {
border-bottom: 0;
padding-bottom: 0;
}
details {
padding: 0.7rem 1rem;
}
summary {
cursor: pointer;
font-weight: bold;
padding: 0.7rem 1rem;
margin: -0.7rem -1rem;
word-break: break-all;
}
details[open] > summary + * {
margin-top: 0;
}
details[open] > summary {
margin-bottom: 0.5rem;
}
details[open] > :last-child {
margin-bottom: 0;
}

table {
border-collapse: collapse;
margin: 1.5rem 0;
}
td,
th {
border: 1px solid var(--border);
text-align: start;
padding: 0.5rem;
}
th {
background-color: var(--accent-bg);
font-weight: bold;
}
tr:nth-child(even) {

background-color: var(--accent-bg);
}
table caption {
font-weight: bold;
margin-bottom: 0.5rem;
}

textarea,
select,
input {
font-size: inherit;
font-family: inherit;
padding: 0.5rem;
margin-bottom: 0.5rem;
color: var(--text);
background-color: var(--bg);
border: 1px solid var(--border);
border-radius: var(--standard-border-radius);
box-shadow: none;
max-width: 100%;
display: inline-block;
}
label {
display: block;
}
textarea:not([cols]) {
width: 100%;
}

select:not([multiple]) {
background-image: linear-gradient(45deg, transparent 49%, var(--text) 51%),
linear-gradient(135deg, var(--text) 51%, transparent 49%);
background-position: calc(100% - 15px), calc(100% - 10px);
background-size: 5px 5px, 5px 5px;
background-repeat: no-repeat;
padding-inline-end: 25px;
}
*[dir="rtl"] select:not([multiple]) {
background-position: 10px, 15px;
}

input[type="checkbox"],
input[type="radio"] {
vertical-align: middle;
position: relative;
width: min-content;
}
input[type="checkbox"] + label,
input[type="radio"] + label {
display: inline-block;
}
input[type="radio"] {
border-radius: 100%;
}
input[type="checkbox"]:checked,
input[type="radio"]:checked {
background-color: var(--accent);
}
input[type="checkbox"]:checked::after {

content: " ";
width: 0.18em;
height: 0.32em;
border-radius: 0;
position: absolute;
top: 0.05em;
left: 0.17em;
background-color: transparent;
border-right: solid var(--bg) 0.08em;
border-bottom: solid var(--bg) 0.08em;
font-size: 1.8em;
transform: rotate(45deg);
}
input[type="radio"]:checked::after {

content: " ";
width: 0.25em;
height: 0.25em;
border-radius: 100%;
position: absolute;
top: 0.125em;
background-color: var(--bg);
left: 0.125em;
font-size: 32px;
}

@media only screen and (max-width: 720px) {
textarea,
select,
input {
width: 100%;
}
}

input[type="color"] {
height: 2.5rem;
padding: 0.2rem;
}

input[type="file"] {
border: 0;
}

hr {
border: none;
height: 1px;
background: var(--border);
margin: 1rem auto;
}
mark {
padding: 2px 5px;
border-radius: var(--standard-border-radius);
background-color: var(--marked);
color: black;
}
img,
video {
max-width: 100%;
height: auto;
border-radius: var(--standard-border-radius);
}
figure {
margin: 0;
display: block;
overflow-x: auto;
}
figcaption {
text-align: center;
font-size: 0.9rem;
color: var(--text-light);
margin-bottom: 1rem;
}
blockquote {
margin-inline-start: 2rem;
margin-inline-end: 0;
margin-block: 2rem;
padding: 0.4rem 0.8rem;
border-inline-start: 0.35rem solid var(--accent);
color: var(--text-light);
font-style: italic;
}
cite {
font-size: 0.9rem;
color: var(--text-light);
font-style: normal;
}
dt {
color: var(--text-light);
}

code,
pre,
pre span,
kbd,
samp {
font-family: var(--mono-font);
color: var(--code);
}
kbd {
color: var(--preformatted);
border: 1px solid var(--preformatted);
border-bottom: 3px solid var(--preformatted);
border-radius: var(--standard-border-radius);
padding: 0.1rem 0.4rem;
}
pre {
padding: 1rem 1.4rem;
max-width: 100%;
overflow: auto;
color: var(--preformatted);
}

pre code {
color: var(--preformatted);
background: none;
margin: 0;
padding: 0;
}



progress {
width: 100%;
}
progress:indeterminate {
background-color: var(--accent-bg);
}
progress::-webkit-progress-bar {
border-radius: var(--standard-border-radius);
background-color: var(--accent-bg);
}
progress::-webkit-progress-value {
border-radius: var(--standard-border-radius);
background-color: var(--accent);
}
progress::-moz-progress-bar {
border-radius: var(--standard-border-radius);
background-color: var(--accent);
transition-property: width;
transition-duration: 0.3s;
}
progress:indeterminate::-moz-progress-bar {
background-color: var(--accent-bg);
}
dialog {
max-width: 40rem;
margin: auto;
}
dialog::backdrop {
background-color: var(--bg);
opacity: 0.8;
}
@media only screen and (max-width: 720px) {
dialog {
max-width: 100%;
margin: auto 1em;
}
}

.notice {
background: var(--accent-bg);
border: 2px solid var(--border);
border-radius: 5px;
padding: 1.5rem;
margin: 2rem 0;
}

strong{
color:#d81b60;
}
em {
color:#e0467e; 
}
hr
{
border: 1px;
clear: both;
display: block;
width: 100%;
height: 1px;

background-color:#686868
}
</style>
</head>
<body>
<header id="title-block-header">
<h1 class="title">Your Digest for Thursday, Jun 29, 2023 11:59 PM</h1>
</header>
<hr />
<p><strong>Beta adrenergic</strong> agonists are the <em>most potent and rapidly acting bronchodilator medications available</em> for asthma treatment. Beta agonists interact with beta adrenergic receptors on a variety of cells to relax bronchial smooth muscle, decrease mast cell mediator release, inhibit neutrophil, eosinophil, and lymphocyte functional responses, increase mucociliary transport, and affect vascular tone and edema formation</p>
<p>The LABA formoterol has a rapid onset of action (similar to albuterol); combination inhalers containing glucocorticoid-formoterol can be used in some settings for relief of acute symptoms and for maintenance (off-label in the United States). <em>LABAs should never be prescribed as monotherapy</em>.</p>
<p>Tolerance to beta agonists can occur due to down regulation of beta receptors. This is problematic in patients who overuse their beta agonists instead of avoiding triggers.</p>
<hr />
<h1 id="hepatocellular-carcinoma">Hepatocellular carcinoma</h1>
<blockquote>
<p><strong>75 percent of primary liver tumors are HCC</strong>, with <em>cholangiocarcinoma ‚âà remaining 25%</em></p>
<p>The majority of HCC cases occur in the <strong>setting of chronic liver disease</strong>.<br />
HCC is an <strong>aggressive</strong> tumour.</p>
</blockquote>
<h2 id="prognostic-factors">prognostic factors</h2>
<ol>
<li>The severity of the underlying liver disease</li>
<li>Tumor size</li>
<li>Extension of the tumor into adjacent structures</li>
<li>The presence or absence of metastases</li>
</ol>
<p><em>Extrahepatic metastases</em> occur as a component of <em>disease recurrence</em> after <em>locoregional therapy</em> in 5 to 25 percent of patients. üòì</p>
<h2 id="epidemiology">Epidemiology</h2>
<p>6th commonest cancer worldwide.<br />
Male to by female : 3:1</p>
<blockquote>
<p>[!INFO] Cirrhocis and chronic Hep infection is the main theme here<br />
HCC Mainly occurs in background of <strong>chronic hep B</strong> infection or <strong>cirrhosis</strong>.</p>
</blockquote>
<ul>
<li><p>About <em>50% of cases are due to HBV</em> infection and <em>20% due to chronic HCV</em>.</p>
<ul>
<li>Developing cirrhosis in <em>background of</em> chronic HBV infection <strong>massively</strong> increases risk.</li>
<li>Factors increasing risk of HCC in background of chornic <strong>HBV</strong>:
<ul>
<li>Presence of cirrhosis as above</li>
<li>HBeAg +ve</li>
<li>High viral load (high HBV DNA level)</li>
<li>High HBsAg</li>
<li>Viral coinfection with HCV or Hep D virus</li>
</ul></li>
<li>Similar story for HCV -&gt; HCC occurs almost exclusively in patient with chronic HCC who <em>have developed cirrhocis</em>. (i.e Cirrhosis due to HCV is a significant risk factor)</li>
<li><em>It is generally believed that HCC arises in the setting of rapid cellular turnover and the chronic inflammatory state induced by HCV</em></li>
</ul></li>
<li><p>Chronic HDV is a risk factor for HCC.</p></li>
<li><p>Environmental risk factors:</p>
<ul>
<li>Aflatoxin B1 - mycotoxin present in corn</li>
<li>Betel nut chewing!üò±</li>
</ul></li>
<li><p>Lifestyle</p>
<ul>
<li>Alcohol - alcoholic cirrhosis; Alcohol can act <em>synergistically</em> with other coexisting HCC risk factors</li>
</ul></li>
<li><p>Metabolic</p>
<ul>
<li>NAFLD and NASH are risk factors</li>
</ul></li>
<li><p>30% of patients with cirrhosis of <em>any cause</em> will develop HCC.<br />
Non alcoholic fatty liver and NASH are also risk factors.</p></li>
</ul>
<p><strong>Protective factors against HCC</strong></p>
<ul>
<li>Antiviral therapy in chronic HBV or HCV reduces risk of HCC
<ul>
<li>Successful treatment of chronic HBV/C reduces but doesn&#39;t eliminate HCC risk.</li>
</ul></li>
<li>Prevention : Hep B Vaccination</li>
<li>Drugs
<ul>
<li>Statins, Metformin, Aspirin and other NSAIDS are associated with lower risk of HCC.</li>
</ul></li>
<li>Diet
<ul>
<li>Coffee intake may reduce HCC Risk.</li>
</ul></li>
</ul>
<h2 id="clinical-manifestations-of-hcc">Clinical manifestations of HCC</h2>
<h3 id="decompensation-of-cirrhosis">Decompensation of cirrhosis</h3>
<p>Variceal bleeding / ascites due to portal obstruction.</p>
<h3 id="paraneoplastic-syndromes">paraneoplastic syndromes</h3>
<ul>
<li>Hypoglycemia&lt;- metabolic demand of tumour</li>
<li>hypercalcaemia&lt;- secretion of PTH related protein</li>
<li>Intractable diarrhoea</li>
<li>cutaneous features</li>
<li>erythrocytosis &lt;- EPO secretion
<ul>
<li>usually masked because overall disease causes anaemia</li>
</ul></li>
</ul>
<h3 id="metastasis">Metastasis</h3>
<p>The most common sites of extrahepatic metastases are<br />
<strong>lung</strong>, intra-abdominal lymph nodes, bone [34], and adrenal gland, in that order.</p>
<h2 id="diagnosis-of-hcc">Diagnosis of HCC</h2>
<blockquote>
<p>[!INFO] Diagnosis can be made by <strong>imaging</strong> alone</p>
</blockquote>
<p><strong>AFP</strong> is a <em>glycoprotein</em> that is normally produced during gestation by the fetal liver and yolk sac,<br />
Alpha-Fetoproten level &gt; 20 is a cutoff for further investigation. Sensitivity is only 60%. üòØ<br />
Specificity - 80%.<br />
(So basically it increases the likelihood of the diagnosis )</p>
<blockquote>
<p>AFP isn&#39;t suitable for screening: low sensitivity and specificity</p>
</blockquote>
<p>Elevated AFP also occurs in</p>
<ul>
<li>#pregnancy,</li>
<li>with <strong>tumors of gonadal origin</strong> (both germ cell and non-germ cell [51])</li>
<li><strong>gastric cancer</strong> and other cancers.</li>
</ul>
<p><strong>Diagnosis</strong> can be made with dynamic <em>contrast-enhanced computed tomography (CT)</em> or magnetic resonance imaging <em>(MRI)</em> tailored for liver lesion evaluation.</p>
<blockquote>
<p>Imaging diagnosis can obviate need for biopsy.</p>
</blockquote>
<h5 id="ct-diagnosis-criteria">CT diagnosis criteria</h5>
<ol>
<li>Size &gt; 1 cm</li>
<li><em>arterial phase hyperenhancement</em> ‚¨ÜÔ∏è of center of lesion relative to the liver parenchyma</li>
<li>In the <em>portal venous or delayed phase</em>
<ol>
<li>Central hypoenhancement ‚¨áÔ∏è (relatively to rest of liver)</li>
<li>Enhancing capsule seen</li>
</ol></li>
<li>Growth &gt; 50% in 6 months</li>
</ol>
<h2 id="overview-of-treatment-hcc">Overview of treatment HCC</h2>
<h3 id="treatment-options">Treatment options</h3>
<p>Resection - curative in eligible patients; tumour should not show vascular invasion to be resectable.<br />
Thermal ablation - similar eligibility criteria to resection, but resection generally preferred.</p>
<h1 id="hepatitis-infection">Hepatitis infection</h1>
<blockquote>
<p>Chronic infection = viral presence; doesn&#39;t mean continuous <em>hepatitis</em>. Hepatitis occurs in acute <em>flare ups</em>.</p>
</blockquote>
<h2 id="hepatitis-d-infection">Hepatitis D infection</h2>
<p>It&#39;s a defective virus which required HBV infection in order to infect the host.</p>
<h3 id="coinfection">Coinfection</h3>
<p>HDV + HBV <strong>coninfection</strong> is clinically identical to acute HBV infection and usually <em>transient and self limited.</em> üòÄ<br />
<strong>Higher risk</strong> of <em>[[2023-SEMPaper#Acute Liver Failure|Acute liver failure]]</em> üòï<br />
Risk of chronic HDV infection is same as risk of HBV infection (because persistence of HDV infection is dependent on persistence of HBV.)</p>
<h3 id="superinfection">Superinfection</h3>
<p>i.e patient has been a (diagnosed or undiagnosed) HBV carrier.<br />
can present as severe acute hepatitis or exacerbation of chronic hepatitis.<br />
Clinically we can&#39;t tell if it&#39;s superinfection or acute HBV but serology can distinguish the two.<br />
Progression to <strong>chronic HDV occurs in all!</strong> üò£</p>
<h3 id="chronic-hdv-infection">Chronic HDV infection</h3>
<p><strong>Rapid progression towards cirrhosis</strong>.<br />
Increased risk of <strong>hepatocellular carcinoma</strong> compared to monoinfection.</p>
<blockquote>
<p>[!TIP] Cirrhosis and HCC are closely linked<br />
So it makes sense that rapid progression to cirrhosis and increased risk of HCC occur in chronic HDV infection</p>
</blockquote>
</body>
</html>
